secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-007971
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead prices upsized $625M zero-coupon convertible notes and $216.6M equity offering
--------------------------------------------------------------------------------

- Net proceeds of ~$681.3M from $700M (including over-allotment) of 0.00% convertible notes due 2032.
- Net proceeds of ~$216.6M from equity offering: 3.1M shares at $64.50 plus pre-funded warrants for 1.55M shares.
- Notes convertible at initial price of ~$87.07 (35% premium); capped call transactions entered to reduce dilution.
- Proceeds for general corporate purposes, R&D, commercialization, and potential prepayment of Sixth Street credit facility.
- Offerings priced Jan 7, 2026; equity closes Jan 9, notes close Jan 12, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/0001193125-26-007971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/d94918d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer